RxDoctor Payments DataLook up a doctor →

Samuel Louie, MD

Pulmonary Disease · Sacramento, CANPI 1811972920

Payments from drug & device makers

$2,811,769in general payments, 2019–2025

Across 3,000 payments — averaging $937.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$918K
  • GSK$620K
  • Sanofi$572K
  • Regeneron Healthcare Solutions, Inc.$414K
  • Boehringer Ingelheim$91K
  • Sunovion Pharmaceuticals Inc.$57K
  • plus $139K from 13 others
$12,021in research payments, 2019–2025

Across 5 payments — averaging $2404.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$12K

What the payments were for

  • Consulting fees$103,2894%
  • Speaking & faculty fees$2,273,80181%
  • Travel & lodging$361,94913%
  • Food & beverage$71,7303%
  • Education$9830%
  • Gifts$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,811,769 in reported general payments places this provider in the 95th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California

Medicare billing

Part B allowed, 2024
$12,779
Medicare patients
79
Services billed
130

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab144$529,665
NucalaMepolizumab111$405,590
Fasenra PenBenralizumab55$337,218
TezspireTezepelumab-Ekko35$152,789
Trelegy ElliptaFluticasone/Umeclidin/Vilanter59$46,446
Breo ElliptaFluticasone/Vilanterol69$35,799
Spiriva RespimatTiotropium Bromide39$23,719
Breztri AerosphereBudesonide/Glycopyr/Formoterol26$20,560
Epinephrine58$11,277
SymbicortBudesonide/Formoterol Fumarate25$9,759
DuleraMometasone/Formoterol19$6,135
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate25$4,819
Dexlansoprazole DrDexlansoprazole14$3,962
Albuterol Sulfate HfaAlbuterol Sulfate60$2,398
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$2,095

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKNucala, Trelegy Ellipta, Breo Ellipta$620,303$487,835239 claims
AstraZenecaTezspire, Breztri Aerosphere, Symbicort$918,361$183,10886 claims
Boehringer IngelheimSpiriva Respimat$91,039$23,71939 claims
MerckDulera$86$6,13519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,261 pulmonary disease providers in California.

Other pulmonary disease in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →